News

Learn more about our parent company “Yuhan Corporation by watching this video ...
Read More

Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in development for the treatment of ...
Read More

Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 94-year heritage. As an outpost of Yuhan’s globalization strategy, ...
Read More

Yuhan and AbClon have joined the list of pharmaceutical companies that are in the race to develop a therapeutic antibody for COVID-19. They have identified a multifariously adaptive candidate for ...
Read More

Yuhan Corporation has in-licensed GI Innovation's allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI Innovation’s collaboration to develop next-generation ...
Read More

Yuhan Corporation's global R&D and open innovation strategy - in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then license them out to the ...
Read More

Here’s an update from our business partner Janssen Biotech that JNJ-6372 in combination with Lazertinib (YH25448), a novel third-generation EGFR TKI for advanced NSCLC that Yuhan Corporation out-licensed to them ...
Read More

In 2020, Yuhan Corporation is going to invest the largest amount in history for its R&D program to speed up the development of Lazertinib (YH25448) – the first-line treatment for ...
Read More

With 2020 just around the corner, let's take a look back at our 2019!It has been a wonderful year for us here at Yuhan USA and may the next year ...
Read More